Equities research analysts forecast that Agile Therapeutics Inc (NASDAQ:AGRX) will announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Agile Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.10). Agile Therapeutics posted earnings of ($0.21) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 47.6%. The firm is expected to issue its next earnings results on Monday, May 6th.

On average, analysts expect that Agile Therapeutics will report full-year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.64) to ($0.34). For the next financial year, analysts anticipate that the company will post earnings of ($0.45) per share, with EPS estimates ranging from ($0.76) to $0.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04.

A number of research firms have weighed in on AGRX. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Agile Therapeutics in a research report on Friday, January 11th. Maxim Group reiterated a “buy” rating and set a $3.00 target price on shares of Agile Therapeutics in a research note on Monday, February 11th. Finally, ValuEngine upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 11th.

In related news, Director Abhijeet J. Lele bought 20,000 shares of Agile Therapeutics stock in a transaction on Friday, March 29th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the acquisition, the director now directly owns 37,949 shares of the company’s stock, valued at $58,441.46. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Alfred Altomari bought 25,000 shares of Agile Therapeutics stock in a transaction on Monday, March 25th. The shares were bought at an average cost of $1.54 per share, with a total value of $38,500.00. Following the acquisition, the chief executive officer now directly owns 238,568 shares in the company, valued at $367,394.72. The disclosure for this purchase can be found here. 7.30% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in shares of Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 44,639 shares in the last quarter. BlackRock Inc. grew its position in shares of Agile Therapeutics by 15.7% in the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 18,038 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 226,255 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Agile Therapeutics by 54.3% during the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 430,907 shares during the period. 21.83% of the stock is owned by institutional investors.

NASDAQ AGRX traded down $0.01 during trading hours on Thursday, reaching $1.47. The company’s stock had a trading volume of 2,888 shares, compared to its average volume of 480,756. The firm has a market cap of $63.95 million, a PE ratio of -2.52 and a beta of 0.47. Agile Therapeutics has a 52 week low of $0.23 and a 52 week high of $3.00.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Article: What are the Different Types of Leveraged Buyouts?

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.